In a recent securities filing, Dr. Reddy’s Laboratories Limited, a multinational pharmaceutical company based in India, disclosed that the U.S. Securities and Exchange Commission ended its bribery investigation into the company. According to Exhibit 99.1 of the Form 6-K filed by Dr. Reddy’s, the company received a letter from the SEC dated February 23, 2026, which stated that the SEC had ended its investigation and chose not to recommend an enforcement action at this time. Dr. Reddy’s said that the SEC’s inquiry had been initiated following a self-disclosure by Dr. Reddy’s to the SEC, the U.S. Department of Justice, and the Securities Exchange Board of India (“SEBI”).
More specifically, following an anonymous complaint regarding allegations of improper payments made to healthcare professionals in Ukraine, and possibly other countries, the Company had engaged a U.S. law firm and conducted an internal investigation. The company also said it had disclosed the matter to enforcement authorities and had fully cooperated with their investigations. The Form 6-K did not provide an update on the status of the DOJ or SEBI investigations.